2024-518464-12-00RecruitingPhase 4
POPular GUILTY PILOT: Genotype-guided Clopidogrel monotherapy
Source: EU CTIS (euclinicaltrials.eu) · Last updated 29 Jan 2026
Brief summary (registry, in English)
1. To assess ischemic risk (i.e. efficacy) of genotype-guided clopidogrel monotherapy during the first 6 months following successful PCI in NSTE-ACS patients. 2. To assess bleeding risk (i.e. safety) of genotype-guided clopidogrel monotherapy during the first 6 months following successful PCI in NSTE-ACS patients.
- Status (registry)
- Recruiting
- Phase (registry)
- Phase 4
- Study type
- Interventional
- Enrollment
- 200 (estimated)
- First submitted
- 26 Sept 2024
- Start date
- 15 Oct 2024
- Lead sponsor
- Sint Antonius Ziekenhuis Stichting
- Diseases
- Coronary artery disease
- EU CT number
- 2024-518464-12-00
- EudraCT number
- 2022-003061-38
What you commit to
- Study type: Interventional · Phase 4
- Planned participants: 200
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of EU CTIS (euclinicaltrials.eu). It describes the study design.
AI-kivonat: who the study is looking for
Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with a heart attack or unstable angina (NSTE-ACS) who had a successful stent procedure (PCI) and have a certain CYP2C19 gene type.
- Age
- 18 years or older
- Sex
- All sexes can join
- Disease stage
- NSTE-ACS (NSTEMI or unstable angina) with a successful PCI, as judged by the treating doctor
- Earlier treatment
- People who already need dual antiplatelet therapy (DAPT) at admission cannot join. People taking oral blood thinners (anticoagulants) cannot join.
- Biomarker or test result
- CYP2C19 extensive or ultra-rapid metabolizer
Main reasons for not taking part
- CYP2C19 poor or intermediate metabolizer
- Planned surgery within 6 months of the PCI
- Pregnant or breastfeeding at enrolment
- Allergy or contraindication to aspirin or clopidogrel
- Recent stroke, TIA or bleeding inside the skull
Read by machine on 9 Nov 2026.
Who cannot take part
Copied verbatim from EU CTIS (euclinicaltrials.eu) and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Planned surgical intervention within 6 months of PCI
- Participation in another trial with an investigational drug or device
- Concurrent use of oral anticoagulants (e.g. because of atrial fibrillation)
Other illness
- Known allergy or contraindication for aspirin or clopidogrel.
- High-risk features for PCI including left main disease, chronic total occlusion, bifurcation lesion requiring 2-stent treatment, saphenous or arterial graft lesion, severely calcified lesion requiring the use of the Rotablator system, ≥3 treated vessels, ≥ 3 stents implanted and total stent length >60 mm
- Recent stroke, transient ischemic attack (TIA) or intracranial bleeding
- Severe hepatic impairment (Child Pugh class C)
Other
- CYP2C19 poor or intermediate metabolizer
- Pregnant or breastfeeding women at time of enrolment
- Ongoing indication for DAPT at admission (e.g. due to recent PCI or ACS)
Who the study is looking for
- Age 18 or older
- Clinical diagnosis of NSTE-ACS (i.e. NSTEMI or unstable angina)
- Successful PCI (according to the treating physician)
- CYP2C19 extensive or ultra-rapid metabolizer
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Save your city in your profile to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Sint Antonius Ziekenhuis Stichting | Nieuwegein | Netherlands | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.